fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth



Status:Completed
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/16/2018
Start Date:June 8, 2015
End Date:June 27, 2017

Use our guide to learn which trials are right for you!

Pilot Study to Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth

The investigators propose the use of functional photoacoustic microscopy (fPAM) to evaluate
both benign and malignant pigmented lesions for tumor depth. Through fPAM analysis followed
by histological examination, the investigators anticipate that they will be able to
non-invasively determine tumor depth of pigmented lesions (moles and melanoma). In melanoma,
tumor depth (Breslow's depth) is not only an important prognostic indicator, but also directs
surgical treatment. The ultimate goal is to develop a sensitive clinical tool that will allow
non-surgical evaluation of pigmented lesions, which eventually, will aid in melanoma
diagnosis and management - potentially an earlier and more definitive surgical management.

In addition, the investigators propose to use the combination of fPAM and single-cell PAM to
respectively image CTCs in trunk vessels and cuticle capillaries. Based on the investigators'
murine models, the investigators anticipate that they will be able to differentiate CTCs from
other blood cells and reliably calculate CTC concentration in a non-invasive manner. CTC
concentration has been demonstrated to be a valuable indicator of a melanoma's metastatic
potential and a potential tool in evaluating treatment efficacy. The ultimate goal is to
develop a sensitive imaging device that will allow accurate evaluation of the risk of
melanoma recurrence and metastases, that may facilitate treatment monitoring.


Inclusion Criteria:

Outcome Measure #1 and #2

- Healthy individuals with pigmented lesions or a partially biopsied melanoma whose
treatment plan includes excision

- Participants must be 18 years or older

- Participants must be able to understand and willing to sign a written informed consent
document

Outcome Measures #3 and #4

- Patients with either cutaneous, visceral or brain melanoma metastases.

- Participants must be 18 years or older.

- Participants must be Eastern Cooperative Oncology Group (ECOG) status 0-3.

- Participants must be able to understand and willing to sign a written informed consent
document.

Exclusion Criteria:

- Minors, pregnant patients, incarcerated individuals, and individuals unable to give
informed consent will be excluded from this study

- ECOG status > 3
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Lynn Cornelius, M.D.
Phone: 314-362-8171
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials